MBRX Reports Q1 2026 $8.3M Financing, 40% Remission Rate in AML Trial
Moleculin Biotech, Inc. · PHARMACEUTICAL PREPARATIONS · Now $2.64
+29% in 7d after detection
Post-detection moves
1h
—
1d
-0.9%
3d
+11%
7d
+29%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS